Cytokinetics Starts Trial For CK-586 In HFpEF
Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...
STAT9d
Cytokinetics is not looking to be acquired, CEO says
The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Canaccord Genuity analyst Caitlin Burrows initiated coverage on Orthofix Medical Inc. OFIX with a Buy rating and announced a ...
Yahoo Finance5d
Cytokinetics, Incorporated (CYTK)
Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its aspirational Vision 2030 ...
news.stocktradersdaily20h
(CYTK) Technical Pivots with Risk Controls
Technical analysis for Cytokinetics Incorporated CYTK including support levels resistance levels and stop losses for CYTK ...
S&P 500 Futures Rise in Premarket Trading; Trump Media & Tech, Cytokinetics Lag
With U.S. stock markets set to open in two hours, LandBridge Co. LLC (LB) was up 4.6% in pre-market trading, and Leonardo DRS Inc. (DRS) was up 4.6%.
Yahoo Finance8d
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its ...
Benzinga.com9d
STAT+: Cytokinetics is not looking to be acquired, CEO says
SAN FRANCISCO — Cytokinetics CEO Robert Blum is very clear. The company — on track to secure U.S. approval in September for a drug to treat a serious heart condition — is not for sale.
Cytokinetics’ Innovative CK-586 Advances Bolster Buy Rating Amid HFpEF Promise
H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on CYTK stock, giving a Buy rating on January 14.Invest with ...